Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026

Leaders from Parabilis Medicines, HawkEye 360 and Cerebras joined investors and leading clinicians at the firm's 2026 Celebration in Toronto

TORONTO, Sept. 28, 2026 /PRNewswire/ -- Sixty Degree Capital ("SDC"), a global, multi-stage venture capital firm investing across technology and healthcare, continued its strong portfolio momentum in 2026. Building on the firm's history of successful exits, five SDC portfolio companies have completed initial public offerings in 2026, including two record-setting offerings.

SpaceX, Parabilis Medicines, Cerebras, HawkEye 360 and Lime each began trading on U.S. exchanges between May and July. SpaceX's offering of approximately US$75 billion is the largest IPO in history, and Parabilis Medicines' US$770 million offering is the largest biotech IPO in history. GrubMarket has also filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission.

"A public listing happens in a single day, but it rests on years of work that most people never see," said Robert Guo, President of Sixty Degree Capital. "This year's listings add to a record our founders have been building since the firm's earliest days. Each of these companies took on hard problems at the frontier of science and technology and executed with real discipline. We are proud to continue as their partner, and we remain focused on backing the companies that will define the decade ahead."

SDC marked this year's milestones at its 2026 Celebration, held on August 11 at the Donalda Club in Toronto. The evening convened founders, investors, scientists, clinicians and partners from across the firm's network, with a program that followed the path from scientific discovery to global scale.

Dr. Mathai Mammen, Chief Executive Officer of Parabilis Medicines, joined SDC Managing Director Dr. Cheryl Kuai in conversation on building biotechnology companies and translating breakthrough science into new medicines. John Serafini, Chief Executive Officer of HawkEye 360, and Nish Sinnadurai, Senior Vice President of Engineering and Canada Country Manager at Cerebras, spoke to the rise of space-based intelligence and the compute infrastructure behind the next generation of artificial intelligence, respectively.

The program closed with a panel on longevity and healthspan, moderated by Dr. Kenneth Grisé, Principal at SDC. Dr. Douglas Vaughan, Founding Director of the Potocsnak Longevity Institute and Chief Academic Officer of Northwestern Medicine, drew on decades of research into the biology of aging. Dr. Hubert Walinski, Chief Scientific Officer, Life Sciences at Portland Holdings, offered a pharmaceutical industry view, and James Mayer, Chief Operating Officer of CABHI and Partner at CABHI Ventures, spoke to innovation in aging and brain health.

This year's listings are the latest outcome of an approach that has guided SDC since its founding in 2018. Its investment approach rests on people, timing and sector expertise, applied by specialized teams of former founders, operators, PhDs, research scientists and investment professionals. That depth allows SDC to recognize potential early, evaluate complex opportunities with conviction and remain a steady partner as companies grow. As innovation across technology and healthcare accelerates, SDC continues to focus on partnering with the founders building what comes next.

About Sixty Degree Capital

Sixty Degree Capital is a global multi-stage venture capital firm based in Toronto. The firm invests in category-defining companies across technology and healthcare, primarily in the United States, with select investments globally. In technology, SDC invests across artificial intelligence, space, defence, cybersecurity and digital infrastructure. In healthcare, SDC invests in pioneering biotechnology and healthcare technology companies that address significant unmet medical needs and have the potential to transform patient care. These investments are underpinned by deep scientific, technical and investment expertise across oncology, immunology, cardiovascular disease, central nervous system disorders and healthcare technology. Its multidisciplinary team partners with exceptional founders from early growth through the public markets.

This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or interests in any fund managed by Sixty Degree Capital.

SOURCE Sixty Degree Capital